logo

BEAM

Beam Therapeutics·NASDAQ
--
--(--)
--
--(--)
3.56 / 10
Netural

Fundamental scrutiny shows concerning metrics: current assets turnover ratio and fixed assets turnover ratio are low (0.0259 and 0.2334 respectively), signaling inefficiency in asset utilization. Although revenue-MV and profit-MV are positive, the stock's overall fundamental score is only 3.6/10, reinforcing a defensive stance.

Fundamental(3.56)SentimentTechnical

Analysis Checks(5/10)

Revenue-MV
Value-3.43
Score2/3
Weight22.57%
1M Return11.69%
Inventory turnover ratio
Value47.85
Score3/3
Weight8.69%
1M Return5.26%
Gross profit margin (%)
Value100.00
Score3/3
Weight19.88%
1M Return10.80%
Profit-MV
Value0.46
Score2/3
Weight14.81%
1M Return7.79%
PB-ROE
Value0.80
Score0/3
Weight6.76%
1M Return3.56%
Current assets turnover ratio
Value0.03
Score0/3
Weight-2.71%
1M Return-1.88%
Fixed assets turnover ratio
Value0.23
Score1/3
Weight-2.35%
1M Return-1.64%
Asset-MV
Value-0.50
Score1/3
Weight17.95%
1M Return8.74%
Cash-MV
Value-0.07
Score2/3
Weight14.83%
1M Return7.73%
Net profit / Total profit (%)
Value100.00
Score0/3
Weight-0.44%
1M Return-0.30%
Is BEAM fundamentally strong?
  • BEAM scores 3.56/10 on fundamentals and holds a Fair valuation at present. Backed by its -38.16% ROE, -744.41% net margin, -6.75 P/E ratio, 2.79 P/B ratio, and -179.11% earnings growth, these metrics solidify its Netural investment rating.